The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Launches Edoxaban in US
February 10, 2015
- Sandoz K.K. Names Mr Hasegawa as New President
February 10, 2015
- Takeda Cuts Costs of 19.5 Billion Yen by December 2014
February 9, 2015
- Ethical Drug Sales Up 2.5% in December: Crecon Report
February 9, 2015
- Astellas to Set Up New Panel on Global Management
February 6, 2015
- Eisai Discloses Option Rights for AD Treatment under Deal with Biogen Idec
February 6, 2015
- Novartis Pharma Should Take Suspension Order Serious: Mr Tsuchiya of JSHP
February 5, 2015
- Daiichi Sankyo Initiates PIII Studies of Mirogabalin in Asia Including Japan
February 5, 2015
- Nipro’s Subsidiary to Build New Factory Eyeing Generic Market Expansion
February 5, 2015
- Wave of Downsizing (3): Mid-Sized Players Muted amid Industry’s Job-Shedding Drive
February 5, 2015
- Belsomra Again Grabs Number 1 Spot in December Anterio Ranking
February 4, 2015
- AbbVie Publishes Japanese PIII Study Results for Hepatitis C Treatment
February 4, 2015
- Astellas to Disclose Detailed Clinical Study Data on Approved Drugs
February 4, 2015
- Wave of Downsizing (2): Job Cuts at Non-Japanese Makers Also Come to Fore
February 4, 2015
- Astellas, Osaka University Join Hands in Cell Therapy Research
February 3, 2015
- Sumitomo Dainippon Revving Up “Post-Latuda” Development Drive
February 3, 2015
- 2014 Was “Difficult Year” as Generics Gained Ground: Kyowa Kirin Pres.
February 3, 2015
- Takeda Terminates Development of Combined Quadruple Vaccine
February 3, 2015
- Wave of Downsizing (1): Major Japan Drug Makers Offer Voluntary Redundancies
February 3, 2015
- Drug Price Cuts, Generic Erosion Weigh Kyowa Kirin Earnings
February 2, 2015
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…